Pulmonx Corp (NASDAQ: LUNG)

Pulmonx is a commercial stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema a form of chronic obstructive pulmonary disease. The company’s solution includes the Zephyr Valve the Chartis System and the LungTraX Platform. It operates in the medical device industry focusing on pulmonary therapies.

Pulmonx generates revenue primarily from the sale of Zephyr Valves and associated delivery catheters. Additional revenue comes from the Chartis System which includes balloon catheters usage fees and console sales and from the LungTraX Platform which provides software access and related services. The company sells its products to hospitals and health care providers mainly pulmonologists and interventional specialists through a direct sales force in the United States and a mix of direct and distributor channels internationally.

Pulmonx holds a leading position in the minimally invasive lung volume reduction market for severe emphysema competing against devices such as the Spiration Valve System from Olympus and the InterVapor System from Broncus Medical. The company differentiates itself through a robust body of clinical evidence demonstrating durability and safety proprietary patient assessment tools like the LungTraX Platform and Chartis System and comprehensive reimbursement and clinical support programs that facilitate adoption. Its inclusion in major treatment guidelines and broad patent portfolio further reinforce its competitive stance.

Pulmonx sells its products to hospitals and health care providers primarily serving pulmonologists and interventional pulmonologists who perform the procedures as well as the broader health care systems that reimburse the treatment. No specific customer names are disclosed in the filing.